Drugs Made In America Acquisition Corp. (DMAAR) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Drugs Made In America Acquisition Corp. (DMAAR:NASDAQ), powered by AI.

Current Price
$0.10
Sector
Unknown
What is the Drugs Made In America Acquisition Corp. stock price forecast?

Drugs Made In America Acquisition Corp. is currently trading at $0.10. View real-time AI analysis on Alpha Lenz.

What is Drugs Made In America Acquisition Corp. insider trading activity?

View the latest insider trading data for Drugs Made In America Acquisition Corp. on Alpha Lenz.

What is Drugs Made In America Acquisition Corp.'s P/E ratio?

View Drugs Made In America Acquisition Corp.'s valuation metrics on Alpha Lenz.

Drugs Made In America Acquisition Corp.

NASDAQ · DMAAR
$0.10+0.00(+0.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Drugs Made In America Acquisition Corp.'s future dividend policy...

Company Overview

Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) organized to identify and merge with one or more businesses in the pharmaceutical sector. Its primary function is to source acquisition opportunities that can establish a comprehensive, domestically-focused drug manufacturing and distribution platform. The company is particularly focused on advancing U.S.-based pharmaceutical production, aiming to reduce dependence on overseas suppliers by investing in advanced manufacturing technologies and supporting the onshoring of critical supply chains. This approach not only aims to enhance the reliability and cost-efficiency of medication supply but also has implications for national security and job creation within the United States. Under the leadership of a seasoned management and advisory team with deep industry experience, Drugs Made In America Acquisition Corp. positions itself at the intersection of healthcare innovation and industrial policy, seeking to address market and strategic needs within the U.S. pharmaceutical landscape.

CEOMs. Lynn Stockwell
SectorUnknown
IndustryUnknown
0

Company Statistics

Profile

N/AMarket Cap
N/ARevenue
0.00Shares Out
0Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

N/AROA
N/AROE
N/AROIC

Financial Health

N/ACash & Cash Equivalents
N/ANet Debt
N/ADebt/Equity
N/AInterest Cov

Frequently Asked Questions

Drugs Made In America Acquisition Corp. (ticker: DMAAR) is a company listed on NASDAQ in the Unknown sector (Unknown).

The current price is $0.1 with a P/E ratio of -x and P/B of -x.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Drugs Made In America Acquisition Corp. (DMAAR) Stock Forecast 2026 $0.10 — Price, Financials & Analyst Targets | Alpha Lenz